Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy

References

• Barre-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013;11:877–883.
   PubMed Web of Science ®Google Scholar
• Collier DA, Monit C, Gupta RK. The impact of HIV-1 drug escape on the global treatment landscape. Cell Host Microbe. 2019;26:48–60.
   PubMed Web of Science ®Google Scholar
• Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692–698.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation. Nature. 2019;568:244–248.
   PubMed Web of Science ®Google Scholar
• Peterson CW, Kiem HP. Lessons from London and Berlin: designing A scalable gene therapy approach for HIV cure. Cell Stem Cell. 2019;24:685–687.
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014;161:319–327.
   PubMed Web of Science ®Google Scholar
• Cummins NW, Rizza S, Litzow MR, et al. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. PLoS Med. 2017;14:e1002461.
   PubMed Web of Science ®Google Scholar
• Xu L, Wang J, Liu Y, et al. CRISPR-Edited Stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019;381:1240–1247.
   PubMed Web of Science ®Google Scholar
• Kordelas L, Verheyen J, Beelen DW, et al. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med. 2014;371:880–882.
   PubMed Web of Science ®Google Scholar
• Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35–40.
   PubMed Web of Science ®Google Scholar
• Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis. 2008;197:266–269.
   PubMed Web of Science ®Google Scholar
• Hayashi T, MacDonald LA, Takimoto T. Influenza A virus protein PA-X contributes to viral growth and suppression of the Host antiviral and immune responses. J Virol. 2015;89:6442–6452.
   PubMed Web of Science ®Google Scholar
• Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012;10:279–290.
   PubMed Web of Science ®Google Scholar
• Hildinger M, Dittmar MT, Schult-Dietrich P, et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol. 2001;75:3038–3042.
   PubMed Web of Science ®Google Scholar
• Egelhofer M, Brandenburg G, Martinius H, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol. 2004;78:568–575.
   PubMed Web of Science ®Google Scholar
• Liu L, Wen M, Zhu Q, et al. Glycosyl phosphatidylinositol-anchored C34 peptide derived from human immunodeficiency virus type 1 Gp41 Is a potent entry inhibitor. J Neuroimmune Pharmacol. 2016;11:601–610.
   PubMed Web of Science ®Google Scholar
• Leslie GJ, Wang J, Richardson MW, et al. Potent and broad Inhibition of HIV-1 by a peptide from the gp41 heptad repeat-2 domain conjugated to the CXCR4 amino terminus. PLoS Pathog. 2016;12:e1005983.
   PubMed Web of Science ®Google Scholar
• Falkenhagen A, Joshi S. Genetic strategies for HIV treatment and prevention. Mol Ther Nucleic Acids. 2018;13:514–533.
   PubMedGoogle Scholar
• Wen M, Arora R, Wang H, et al. GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology. 2010;7:79.
   PubMed Web of Science ®Google Scholar
• Liu L, Wen M, Wang W, et al. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J Virol. 2011;85:8467–8476.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang W, Matz J, et al. The Glycosylphosphatidylinositol-Anchored Variable region of llama heavy chain-only antibody JM4 efficiently blocks both cell-free and T cell-T cell transmission of human Immunodeficiency Virus Type 1. J Virol. 2016;90:10642–10659.
   PubMed Web of Science ®Google Scholar
• Ye C, Wang W, Cheng L, et al. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv efficiently Protects CD4 T cells from HIV-1 infection and deletion in hu-PBL mice. J Virol. 2017;91:e01389–16.
   PubMed Web of Science ®Google Scholar
• Stephenson KE, Wagh K, Korber B, et al. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu Rev Immunol. 2020;38:673–703.
   PubMed Web of Science ®Google Scholar
• Barouch DH. A step forward for HIV vaccines. Lancet HIV. 2018;5:e338–e339.
   PubMed Web of Science ®Google Scholar
• Alter G, Barouch D. Immune correlate-guided HIV vaccine design. Cell Host Microbe. 2018;24:25–33.
   PubMed Web of Science ®Google Scholar
• Jin H, Tang X, Li L, et al. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cell Mol Immunol. 2021;18:660–674.
   PubMed Web of Science ®Google Scholar
• Tang X, Jin H, Chen Y, et al. A membrane-anchored short-peptide fusion inhibitor fully Protects target cells from infections of HIV-1, HIV-2, and simian immunodeficiency virus. J Virol. 2019;93:e01177–19.
   PubMed Web of Science ®Google Scholar
• Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333:1633–1637.
   PubMed Web of Science ®Google Scholar
• Huang J, Kang BH, Ishida E, et al. Identification of a CD4-binding-site antibody to HIV that evolved near-Pan neutralization breadth. Immunity. 2016;45:1108–1121.
   PubMed Web of Science ®Google Scholar
• Pejchal R, Doores KJ, Walker LM, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 2011;334:1097–1103.
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477:466–470.
   PubMed Web of Science ®Google Scholar
• Huang J, Kang BH, Pancera M, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014;515:138–142.
   PubMed Web of Science ®Google Scholar
• Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491:406–412.
   PubMed Web of Science ®Google Scholar
• deCamp A, Hraber P, Bailer RT, et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2014;88:2489–2507.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang W, Yang L, et al. Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J Virol. 2013;87:1899–1905.
   PubMed Web of Science ®Google Scholar
• Misra A, Gleeson E, Wang W, et al. Glycosyl-Phosphatidylinositol-Anchored anti-HIV Env Single-Chain Variable Fragments interfere with HIV-1 Env processing and viral infectivity. J Virol. 2018;92:e02080–17.
   PubMed Web of Science ®Google Scholar
• de Mendoza C, Barreiro P, Benitez L, et al. Gene therapy for HIV infection. Expert Opin Biol Ther. 2015;15:319–327.
   PubMed Web of Science ®Google Scholar
• Burke BP, Levin BR, Zhang J, et al. Engineering cellular resistance to HIV-1 infection In vivo using a dual therapeutic lentiviral vector. Mol Ther Nucleic Acids. 2015;4:e236.
   PubMedGoogle Scholar
• Herrera-Carrillo E, Berkhout B. Potential mechanisms for cell-based gene therapy to treat HIV/AIDS. Expert Opin Ther Targets. 2015;19:245–263.
   PubMed Web of Science ®Google Scholar
• Herrera-Carrillo E, Berkhout B. Bone marrow gene therapy for HIV/AIDS. Viruses. 2015;7:3910–3936.
   PubMed Web of Science ®Google Scholar
• Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487–491.
   PubMed Web of Science ®Google Scholar
• Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7:319ra206.
   PubMed Web of Science ®Google Scholar
• Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 2016;375:2037–2050.
   PubMed Web of Science ®Google Scholar
• Caskey M, Schoofs T, Gruell H, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23:185–191.
   PubMed Web of Science ®Google Scholar
• van Dorsten RT, Lambson BE, Wibmer CK, et al. Neutralization breadth and potency of Single-Chain variable fragments derived from broadly neutralizing antibodies targeting multiple epitopes on the HIV-1 envelope. J Virol. 2020;94:e01533-19.
   PubMed Web of Science ®Google Scholar
• Reh L, Magnus C, Schanz M, et al. Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission Is strain- and epitope-dependent. PLoS Pathog. 2015;11:e1004966.
   PubMed Web of Science ®Google Scholar
• Gombos RB, Kolodkin-Gal D, Eslamizar L, et al. Inhibitory effect of individual or combinations of broadly neutralizing antibodies and antiviral reagents against cell-free and cell-to-cell HIV-1 transmission. J Virol. 2015;89:7813–7828.
   PubMed Web of Science ®Google Scholar
• Malbec M, Porrot F, Rua R, et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med. 2013;210:2813–2821.
   PubMed Web of Science ®Google Scholar
• Narasimhulu VGS, Bellamy-McIntyre AK, Laumaea AE, et al. Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion. J Biol Chem. 2018;293:6099–6120.
   PubMed Web of Science ®Google Scholar
• Scheid JF, Horwitz JA, Bar-On Y, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535:556–560.
   PubMed Web of Science ®Google Scholar
• Alam M, Kuwata T, Shimura K, et al. Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. Retrovirology. 2016;13:70.
   PubMed Web of Science ®Google Scholar
• Visseaux B, Damond F, Matheron S, et al. Hiv-2 molecular epidemiology. Infect Genet Evol. 2016;46:233–240.
   PubMed Web of Science ®Google Scholar